➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Baxter
McKesson
Johnson and Johnson
Moodys

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,208,073

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,208,073
Title:Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-to- lyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnet- upitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
Abstract: Disclosed is a solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-to- lyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone and its application in methods for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy.
Inventor(s): Fadini; Luca (Giubiasco, CH), Manini; Peter (Giubiasco, CH), Pietra; Claudio (Como, IT), Giuliano; Claudio (Como, IT), Lovati; Emanuela (Mendrisio, CH), Cannella; Roberta (Varese, IT), Venturini; Alessio (Varese, IT), Stella; Valentino J (Lawrence, KS)
Assignee: Helsinn Healthcare SA (Lugano/Pazzallo, CH)
Application Number:15/874,325
Patent Claims: 1. A method for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy, comprising intravenously administering to the human patient, prior to the chemotherapy, a solution comprising a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant and a therapeutically effective amount of palonosetron hydrochloride, in combination with a therapeutically effective amount of dexamethasone.

2. The method of claim 1, wherein the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule and the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base.

3. The method of claim 1, wherein the solution has a concentration of from 2 mg/mL to 5 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule.

4. The method of claim 1, wherein the solution has a concentration of from 5 mg/mL to 15 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule.

5. The method of claim 1, wherein the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule, the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base, and the solution has a concentration of from 2 mg/mL to 5 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule.

6. The method of claim 1, wherein the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule, the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base, and the solution has a concentration of from 5 mg/mL to 15 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule.

7. The method of claim 1, wherein the therapeutically effective amount of dexamethasone comprises 12 mg administered orally on day 1, 8 mg administered orally on day 2, 8 mg administered orally on day 3 and 8 mg administered orally on day 4.

8. The method of claim 1, wherein the method consists of intravenously administering to the human patient, prior to the chemotherapy, a solution comprising a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant and a therapeutically effective amount of palonosetron hydrochloride, in combination with a therapeutically effective amount of dexamethasone.

9. The method of claim 1, wherein the fosnetupitant independently prevents acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy.

10. A method for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy, comprising intravenously administering to the human patient, prior to the chemotherapy, a solution comprising a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant and a therapeutically effective amount of palonosetron hydrochloride, in combination with a therapeutically effective amount of dexamethasone, wherein: (a) the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule; (b) the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base; and (c) the solution has a concentration of from 2 mg/mL to 5 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule.

11. A method for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy, comprising intravenously administering to the human patient, prior to the chemotherapy, a solution comprising a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant and a therapeutically effective amount of palonosetron hydrochloride, in combination with a therapeutically effective amount of dexamethasone, wherein: (a) the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule; (b) the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base; and (c) the solution has a concentration of from 5 mg/mL to 15 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule.

12. A method for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy, consisting of intravenously administering to the human patient, prior to the chemotherapy, a solution comprising a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant and a therapeutically effective amount of palonosetron hydrochloride, in combination with a therapeutically effective amount of dexamethasone, wherein: (a) the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule; (b) the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base; (c) the solution has a concentration of from 2 mg/mL to 5 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule; and (d) the therapeutically effective amount of dexamethasone comprises 12 mg administered orally on day 1, 8 mg administered orally on day 2, 8 mg administered orally on day 3 and 8 mg administered orally on day 4.

13. A method for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy, consisting of intravenously administering to the human patient, prior to the chemotherapy, a solution comprising a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant and a therapeutically effective amount of palonosetron hydrochloride, in combination with a therapeutically effective amount of dexamethasone, wherein: (a) the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule; (b) the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base; (c) the solution has a concentration of from 5 mg/mL to 15 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule; and (d) the therapeutically effective amount of dexamethasone comprises 12 mg administered orally on day 1, 8 mg administered orally on day 2, 8 mg administered orally on day 3 and 8 mg administered orally on day 4.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Mallinckrodt
AstraZeneca
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.